Abstract
Pulmonary involvement is a frequent condition in patients with hematological malignancies. If infectious disease and cardiac failure are still the most frequent causes, other etiologies are being increasingly recognized and represent a difficult challenge in diagnostic terms for the physician. Compared to the estimated annual incidence of venous thromboembolism (VTE) in the general population and in the cancer population, the estimated rate for hematological patients is higher and close to the incidence of VTE in with high-risk solid tumors patients. For instance, VTE has been found in less than 6% of acute leukemia patients, 17% of patients with myeloma and 6–60% of patients with lymphoma. Drug-related pulmonary toxicity is being increasingly described, mainly with “old” drugs with new indications or with new drugs. Radiation pneumonitis is now rare in hematological patients without total body irradiation, but its incidence may be increased by a concomitant drug treatment. It is now admitted that conventional dose anticancer treatment increases the risk of secondary cancers, and this late complication, with the decrease of other complications such as radiation-induced fibrosis, is now one of the most challenging questions needing to be answered. This review addresses the challenge of noninfectious pulmonary involvement in patients with hematological malignancies who are not BMT recipients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Asakura S, Colby TV (1994) Agnogenic myeloid metaplasia with extramedullary hematopoiesis and fibrosis in the lung. Report of two cases. Chest 105:1866–1868
Bartlett RP, Greipp PR, Tefferi A et al (1995) Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc 70:1161–1164
Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80:1568–1574
Camus P, Foucher P Pneumotox® website (1997) Last update 2009 http//pneumotox.com.
Caruso V, Iacoviello L, Di Castelnuovo A et al (2007) Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 5:621–623
Caruso V, Iacoviello L, Castelnuovo D et al (2006) Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1, 752 pediatric patients. Blood 108:2216–2222
Chen CI, Abraham R, Tsang et al (2001) Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplant 27: 177–182
Cordonnier C, Fleury-Feith J, Escudier E et al (1994) Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med 149:788–794
Dingli D, Utz JP, Krowka MJ et al (2001) Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 120:801–808
El Accaoui RN, Shamseddeen WA, Taher AT (2007) Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 97:1031–1036
Falanga A, Marchetti M (2009) Venous thromboembolism in the hematologic malignancies. J Clin Oncol 27: 4848–4857
Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T (2003) High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 98:1239–1242
Guilpain P, Montani D, Damaj G et al (2008) Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases. Respiration 76:295–302
Hirsch A, Vander Els N, Straus DJ et al (1996) Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin’s disease. J Clin Oncol 14: 1297–1305
Khorana AA, Francis CW, Culakova E et al (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104: 2822–2829
Kramer MR, Estenne M, Berkman N et al (1993) Radiation-induced pulmonary veno-occlusive disease. Chest 104: 1282–1284
Ku GH, White RH, Chew HK et al (2009) Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 113:3911–3917
Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107:I17–21
Lombard CM, Churg A, Winokur S (1987) Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest 92:871–876
Lorigan P, Radford J, Howell A et al (2005) Lung cancer after treatment for Hodgkin’s lymphoma: a systematic review. Lancet Oncol 6:773–779
Mauch PM, Kalish LA, Marcus KC et al (1996) Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s disease: long-term analysis of risk factors and outcome. Blood 87:3625–3632
Menon SP, Rajkumar SV, Lacy M et al (2008) Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 112:1522–1528
Metayer C, Curtis RE, Vose J et al (2003) Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101:2015–2023
Mohren M, Markmann I, Jentsch-Ullrich et al (2006) Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer 94:200–202
Ng AK, Bernardo P, Weller E et al (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100:1989–1996
Ottinger H, Belka C, Kozol et al (1995) Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin’s lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 54:186–194
Pezner RD, Horak DA, Sayegh HO et al (1990) Spontaneous pneumothorax in patients irradiated for Hodgkin’s disease and other malignant lymphomas. Int J Radiat Oncol Biol Phys 18:193–198
Shapiro SJ, Shapiro SD, Mill WB et al (1990) Prospective study of long-term pulmonary manifestations of mantle irradiation. Int J Radiat Oncol Biol Phys 19:707–714
Swerdlow AJ, Douglas AJ, Hudson GV et al (1992) Risk of second primary cancers after Hodgkin’s disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 304:1137–1143
Travis LB, Gospodarowicz M, Curtis RE et al (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94:182–192
van Leeuwen FE, Klokman WJ, Stovall M et al (1995) Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 87:1530–1537
Zangari M, Tricot G, Polavaram L et al (2010) Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 28:132–135
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Maitre, B. (2011). Noninfectious Lung Involvement in Patients with Hematological Malignancies (Excluding BMT). In: Azoulay, E. (eds) Pulmonary Involvement in Patients with Hematological Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-15742-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-15742-4_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-15741-7
Online ISBN: 978-3-642-15742-4
eBook Packages: MedicineMedicine (R0)